No relief for Ozempic supply issues

Novo Nordisk has informed the TGA that supply of its diabetes treatment Ozempic will continue to remain "limited" throughout 2025 as it continues to grapple with increased consumer demand worldwide due to off-label prescribing for obesity.

To see the whole article please log in.

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

Retype password

Not a member? Sign up here